The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
© Dueñas-Decamp et al; licensee BioMed Central Ltd. 2012
Received: 19 July 2011
Accepted: 27 January 2012
Published: 27 January 2012
The conserved CD4 binding site (CD4bs) on HIV-1 gp120 is a major target for vaccines. It is a priority to determine sites and structures within the CD4bs that are important for inclusion in vaccines. We studied a gp120 pocket penetrated by W100 of the potent CD4bs monoclonal antibody (mab), b12. We compared HIV-1 envelopes and corresponding mutants that carried blocked W100 pockets to evaluate whether other CD4bs mabs target this site.
All CD4bs mabs tested blocked soluble CD4 binding to gp120 consistent with their designation as CD4bs directed antibodies. All CD4bs mabs tested neutralized pseudovirions carrying NL4.3 wild type (wt) envelope. However, only b12 failed to neutralize pseudoviruses carrying mutant envelopes with a blocked W100 pocket. In addition, for CD4bs mabs that neutralized pseudovirions carrying primary envelopes, mutation of the W100 pocket had little or no effect on neutralization sensitivity.
Our data indicate that the b12 W100 pocket on gp120 is infrequently targeted by CD4bs mabs. This site is therefore not a priority for preservation in vaccines aiming to elicit antibodies targeting the CD4bs.
KeywordsHIV envelope gp120 CD4 binding site neutralization
CD4 binding site monoclonal antibodies investigated
Polymun Sci. GmbH
NIH AIDS Rea. Pr.2
NIH AIDS Rea. Pr.
NIH AIDS Rea. Pr.
Recently, further CD4bs mabs, e.g. 3BNC60  and VRC-PG04  have been reported [13–15]. Like VRC01, VRC03, and HJ16 (studied here), they were derived from so called 'elite neutralizers', HIV-1+ subjects who carried potent neutralizing antbodies active against diverse viral strains. These new mabs are highly potent and have binding specificities that focus on similar gp120 residues to that of VRC01 , which (as confirmed here) does not penetrate the W100 pocket on gp120. The crystal structure of mab 3BNC60 verifies a structure where predicted gp120 contact residues are conserved with those of VRC01 , while a structure of mab VRC-PG04 complexed with a gp120 core shows the same for that mab and confirms no interaction with the W100 pocket on gp120. Diskin et al. also reported that NIH45-46 conferred even more potent neutralization than VRC01. However, the increased potency of this mab was due to increased contact with the gp120 inner domain and bridging sheet determinants without targeting the W100 pocket .
In summary, we investigated whether the W100 pocket on gp120 (a critical target for mab b12) is required for HIV-1 neutralization by other CD4bs mabs. We found that neutralization of pseudovirions carrying primary or T-cell line adapted HIV-1 envelopes was either unaffected or only marginally shifted by the presence of a mutated W100 pocket. These observations contrasted with neutralization by b12, which was severely curtailed by the presence of a mutated W100 pocket for all six HIV-1 envelopes tested. Our data indicate that the W100 pocket on gp120 is not a frequent target among CD4bs mabs and is not required for potent neutralization of diverse primary strains of HIV-1 via the CD4bs.
Availability of supporting data
The data sets supporting the results of this article are available in the Dryad repository http://dx.doi.org/10.5061/dryad.66h5g23t.
List of abbreviations
We thank Paul Peters for his insightful comments and input for this study. We also thank John Mascola (Vaccine Research Center, NIAID) and Robin Weiss (UCL, London) for supportive comments and for help in obtaining mabs VRC01, VRC03 and HJ16 respectively. We thank James Robinson (Tulane University School of Medicine) for providing mab 17b. Our work was supported by NIH grants R01s MH64408, AI089334 and P01 AI082274. We also wish to thank the University of Massachusetts Medical School Center for AIDS Research (CFAR), the NIH AIDS Research and Reference Reagent Program, the Vaccine Research Center, NIH and the Centre for AIDS Reagents, NIBSC, UK, for services and reagents.
- Duenas-Decamp MJ, Peters P, Burton D, Clapham PR: Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol. 2008, 82: 5807-5814. 10.1128/JVI.02585-07.PubMed CentralView ArticlePubMed
- Pantophlet R, Ollmann Sapphire E, Poignard P, Parren PW, Wilson IA, Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2003, 77: 642-658. 10.1128/JVI.77.1.642-658.2003.PubMed CentralView ArticlePubMed
- Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, Eggink D, Melchers M, Busser E, Dankers MM, Groot F, Braakman I, Berkhout B, Paxton WA: The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology. 2008, 5: 10-10.1186/1742-4690-5-10.PubMed CentralView ArticlePubMed
- Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD: Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007, 445: 732-737. 10.1038/nature05580.PubMed CentralView ArticlePubMed
- Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010, 5: e8805-10.1371/journal.pone.0008805.PubMed CentralView ArticlePubMed
- Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Do Kwon Y, Scheid J, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD: Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science. 2010, 330: 1775-1787. 10.1126/science.1196914.PubMed CentralView ArticlePubMed
- Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR: Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. J Virol. 2011, 85: 8954-8967. 10.1128/JVI.00754-11.PubMed CentralView ArticlePubMed
- Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham P: Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008, 5: 5-PubMed CentralView ArticlePubMed
- Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393: 648-659. 10.1038/31405.View ArticlePubMed
- Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, Peden KW: Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses. 1996, 12: 191-194. 10.1089/aid.1996.12.191.View ArticlePubMed
- Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS: Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science. 1987, 236: 819-822. 10.1126/science.3646751.View ArticlePubMed
- Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR: Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol. 2004, 78: 6915-6926. 10.1128/JVI.78.13.6915-6926.2004.PubMed CentralView ArticlePubMed
- Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Olivera TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton D, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC: Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science. 2011, 333: 1633-1637. 10.1126/science.1207227.PubMed CentralView ArticlePubMed
- Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose N, Connors M, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR: Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science. 2011, 333: 1593-1602. 10.1126/science.1207532.PubMed CentralView ArticlePubMed
- Clapham PR, Lu S: Vaccinology: precisely tuned antibodies nab HIV. Nature. 2011, 477: 416-417. 10.1038/477416a.View ArticlePubMed
- Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ: Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. Science. 2011, 334: 1289-1293. 10.1126/science.1213782.PubMed CentralView ArticlePubMed
- Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 2000, 182: 326-329. 10.1086/315698.View ArticlePubMed
- Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD: Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009, 326: 1123-1127. 10.1126/science.1175868.PubMed CentralView ArticlePubMed
- Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM: Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol. 2005, 79: 13060-13069. 10.1128/JVI.79.20.13060-13069.2005.PubMed CentralView ArticlePubMed
- Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S: Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol. 1994, 68: 4001-4008.PubMed CentralPubMed
- Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol. 1991, 65: 489-493.PubMed CentralPubMed
- Zhang MY, Dimitrov DS: Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des. 2007, 13: 203-212. 10.2174/138161207779313669.View ArticlePubMed
- Schutten M, McKnight A, Huisman RC, Thali M, McKeating JA, Sodroski J, Goudsmit J, Osterhaus AD: Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS. 1993, 7: 919-923. 10.1097/00002030-199307000-00003.View ArticlePubMed
- Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, Burda S, Wang XH, Bandres J, Zolla-Pazner S, Holmes H: Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett. 2001, 79: 209-213. 10.1016/S0165-2478(01)00289-9.View ArticlePubMed
- McKeating JA, Thali M, Furman C, Karwowska S, Gorny MK, Cordell J, Zolla Pazner S, Sodroski J, Weiss RA: Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology. 1992, 190: 134-142. 10.1016/0042-6822(92)91199-5.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.